Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Iterum raises funds for new antibiotic

by Michael McCoy
May 29, 2017 | A version of this story appeared in Volume 95, Issue 22

The biotech firm Iterum Therapeutics has raised $65 million in a series B investment round. The cash will help the company complete a Phase III clinical trial of sulopenem, an antibiotic it is developing to treat Gram-negative multi-drug-resistant infections. Iterum was founded in 2015 to license sulopenem from its discoverer, Pfizer. It plans to file a New Drug Application with FDA by the end of 2019.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.